Stock Scorecard



Stock Summary for Regenxbio Inc (RGNX)

Total Score

19 out of 29

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for RGNX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RGNX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RGNX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for RGNX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for RGNX

Company Overview

Company Name Regenxbio Inc
Country USA
Description REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2022
Next Earnings Date

Stock Price History

Last Day Price 22.56
Last Day Volume 272,366
Average Daily Volume 318,344
52-Week High 36.35
52-Week Low 18.69
Last Price to 52 Week Low 20.71 %

Valuation Measures

Trailing PE 13.06
Industry PE 221.12
Sector PE 93.21
5-Year Average PE -1.93
Free Cash Flow Ratio 1.58
Industry Free Cash Flow Ratio 9.61
Sector Free Cash Flow Ratio 37.54
Book Value Per Share Most Recent Quarter 13.02
Price to Book Ratio 1.74
Industry Price to Book Ratio 11.39
Sector Price to Book Ratio 15.42
Price to Sales Ratio Twelve Trailing Months 2.05
Industry Price to Sales Ratio Twelve Trailing Months 43.33
Sector Price to Sales Ratio Twelve Trailing Months 25.17

Share Statistics

Total Shares Outstanding 43,293,600
Market Capitalization 976,703,616
Institutional Ownership 0.00 %

Dividends

Ex-Dividend Date
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth 214.91 %
Reported EPS Past Year -5.12
Reported EPS Prior Year 2.74
Net Income Twelve Trailing Months 73,637,000
Net Income Past Year 127,840,000
Net Income Prior Year -111,250,000
Quarterly Revenue Growth YOY -13.80 %
5-Year Revenue Growth 156.04 %

Balance Sheet

Total Cash Per Share 14.25
Total Cash Most Recent Quarter 617,000,000
Total Cash Past Year 849,300,000
Total Cash Prior Year 522,500,000
Net Cash Position Most Recent Quarter 617,000,000
Net Cash Position Past Year 849,300,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Current Ratio Most Recent Quarter 3.53
Total Stockholder Equity Past Year 764,298,000
Total Stockholder Equity Prior Year 377,753,000
Total Stockholder Equity Most Recent Quarter 563,824,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

MACD -0.43
MACD Signal -0.56
20-Day Bollinger Lower Band 24.35
20-Day Bollinger Middle Band 25.57
20-Day Bollinger Upper Band 26.80
Beta 1.00
RSI 50.13
50-Day SMA 27.11
200-Day SMA 36.60

System

Modified 11/30/2022 1:43:57 AM